Pituitary Society Delphi consensus on the role of radiotherapy for pituitary adenomas.

IF 3.8 2区 医学 Q2 ENDOCRINOLOGY & METABOLISM
Frederic Castinetti, Cecilia Piazzola, John Ayuk, Michael Kosmin, Marco Losa, Hani J Marcus, Alberto M Pereira, Shlomo Melmed, Maria Fleseriu
{"title":"Pituitary Society Delphi consensus on the role of radiotherapy for pituitary adenomas.","authors":"Frederic Castinetti, Cecilia Piazzola, John Ayuk, Michael Kosmin, Marco Losa, Hani J Marcus, Alberto M Pereira, Shlomo Melmed, Maria Fleseriu","doi":"10.1007/s11102-026-01759-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Context: </strong>Radiotherapy is used as second- or third-line treatment after transsphenoidal surgery for both functioning and nonfunctioning pituitary adenomas. Improved precision delivery may reduce side effects, but use overall has declined, partly due to improved surgical technique and advances in medical therapy, partly reflecting a shift from fractionated radiotherapy to stereotactic radiosurgery in appropriately selected patients, and also due to lack of clear, evidence-based guidelines. Questions remain regarding radiotherapy indications, optimal timing, choice of technique, and follow-up for efficacy and side effects. The aim of this Delphi panel was to establish expert consensus in these areas.</p><p><strong>Design: </strong>The Pituitary Society Steering Committee conducted a modified two-round Delphi panel with 29 international experts from five continents, including neuroendocrinologists, neurosurgeons and radiation oncologists.</p><p><strong>Results: </strong>Among the 26 initial statements, 22 (84.6%) reached agreement after Round 1. Four statements were reconsidered in Round 2, together with an additional question, after which 24 of 27 (88.9%) reached consensus. Panelists agreed that radiotherapy indication and timing should be assessed by expert multidisciplinary tumor boards, including a radiation oncologist, with the technique determined according to patient and adenoma characteristics. They emphasized controlling hormonal secretion while waiting for maximal radiotherapy efficacy in functioning adenomas. Long term follow-up > 10 years is required to assess for delayed efficacy, recurrence and side effects, although panelists agreed on the relatively low medium-term risk with modern techniques.</p><p><strong>Conclusion: </strong>Modified Delphi panel provides practical guidance regarding indications, timing, choice of technique and long-term follow-up of radiotherapy in pituitary adenomas. Modern techniques appear as effective and potentially safer vs. previous ones. Further long-term comparative data are needed.</p>","PeriodicalId":20202,"journal":{"name":"Pituitary","volume":"29 5","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13601102/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pituitary","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11102-026-01759-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Context: Radiotherapy is used as second- or third-line treatment after transsphenoidal surgery for both functioning and nonfunctioning pituitary adenomas. Improved precision delivery may reduce side effects, but use overall has declined, partly due to improved surgical technique and advances in medical therapy, partly reflecting a shift from fractionated radiotherapy to stereotactic radiosurgery in appropriately selected patients, and also due to lack of clear, evidence-based guidelines. Questions remain regarding radiotherapy indications, optimal timing, choice of technique, and follow-up for efficacy and side effects. The aim of this Delphi panel was to establish expert consensus in these areas.

Design: The Pituitary Society Steering Committee conducted a modified two-round Delphi panel with 29 international experts from five continents, including neuroendocrinologists, neurosurgeons and radiation oncologists.

Results: Among the 26 initial statements, 22 (84.6%) reached agreement after Round 1. Four statements were reconsidered in Round 2, together with an additional question, after which 24 of 27 (88.9%) reached consensus. Panelists agreed that radiotherapy indication and timing should be assessed by expert multidisciplinary tumor boards, including a radiation oncologist, with the technique determined according to patient and adenoma characteristics. They emphasized controlling hormonal secretion while waiting for maximal radiotherapy efficacy in functioning adenomas. Long term follow-up > 10 years is required to assess for delayed efficacy, recurrence and side effects, although panelists agreed on the relatively low medium-term risk with modern techniques.

Conclusion: Modified Delphi panel provides practical guidance regarding indications, timing, choice of technique and long-term follow-up of radiotherapy in pituitary adenomas. Modern techniques appear as effective and potentially safer vs. previous ones. Further long-term comparative data are needed.

垂体学会德尔福共识放射治疗垂体腺瘤的作用。
背景:对于功能性和非功能性垂体腺瘤,放射治疗是经蝶窦手术后的二线或三线治疗。精准投放的提高可能会减少副作用,但总体使用量有所下降,部分原因是手术技术的改进和医学治疗的进步,部分原因是在适当选择的患者中,从分割放疗转向立体定向放疗,还有一个原因是缺乏明确的循证指南。关于放疗适应证、最佳时机、技术选择以及疗效和副作用的随访等问题仍然存在。德尔菲小组的目的是在这些领域建立专家共识。设计:垂体学会指导委员会与来自五大洲的29位国际专家,包括神经内分泌学家、神经外科医生和放射肿瘤学家,进行了修改后的两轮德尔菲小组。结果:在26个初始陈述中,22个(84.6%)在第一轮后达成一致。在第二轮中重新考虑了四个陈述,以及一个附加问题,之后27人中有24人(88.9%)达成共识。小组成员一致认为,放疗的适应证和时机应由多学科肿瘤专家委员会评估,包括放射肿瘤学家,并根据患者和腺瘤特征确定技术。他们强调控制激素分泌,同时等待功能腺瘤的最大放射治疗效果。尽管专家组成员一致认为现代技术的中期风险相对较低,但仍需要10年的长期随访来评估延迟疗效、复发和副作用。结论:改进的德尔菲面板对垂体腺瘤放疗的适应证、时机、技术选择和长期随访具有实用的指导意义。与以前的技术相比,现代技术似乎更有效,而且可能更安全。需要进一步的长期比较数据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pituitary
Pituitary 医学-内分泌学与代谢
CiteScore
7.10
自引率
7.90%
发文量
90
审稿时长
6 months
期刊介绍: Pituitary is an international publication devoted to basic and clinical aspects of the pituitary gland. It is designed to publish original, high quality research in both basic and pituitary function as well as clinical pituitary disease. The journal considers: Biology of Pituitary Tumors Mechanisms of Pituitary Hormone Secretion Regulation of Pituitary Function Prospective Clinical Studies of Pituitary Disease Critical Basic and Clinical Reviews Pituitary is directed at basic investigators, physiologists, clinical adult and pediatric endocrinologists, neurosurgeons and reproductive endocrinologists interested in the broad field of the pituitary and its disorders. The Editorial Board has been drawn from international experts in basic and clinical endocrinology. The journal offers a rapid turnaround time for review of manuscripts, and the high standard of the journal is maintained by a selective peer-review process which aims to publish only the highest quality manuscripts. Pituitary will foster the publication of creative scholarship as it pertains to the pituitary and will provide a forum for basic scientists and clinicians to publish their high quality pituitary-related work.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书